Your new post is loading...
Ektomun® is a member of the highly innovative, validated family of Triomab® antibodies. It combines the halves of two distinct full-size antibodies, a GD2-specific mouse antibody and a T -cell specific rat antibody, in one molecule.
GD2 is a clinically validated tumor target opening many potential applications for ektomun®. It is broadly present in tumors of neuroectodermal origin, including small cell lung cancer (SCLC), melanoma, neuroblastoma and glioblastoma. In healthy tissues, however, GD2 expression is strictly limited to very few, distinct cell types.
Due to its trifunctional design, ektomun® can simultaneously bind to GD2, expressed by tumor cells, to a T-cell and, via its Fc-region, to an accessory cell of the innate immune system, as e.g. macrophages, dendritic or NK cells.
The resulting tri-cell-complex triggers multiple immune mechanisms at the same time. Not only are tumor cells specifically and potently destroyed, but a long-lasting anti-tumor immunity is also induced – an effect that can otherwise only be achieved through vaccination.
Via Krishan Maggon
